Mesoblast Limited (MESO)

Market Cap	1.97B
Revenue (ttm)	17.20M
Net Income (ttm)	-102.14M
Shares Out	1.28B
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	213,527
Open	16.19
Previous Close	15.62
Day's Range	15.87 - 16.31
52-Week Range	9.61 - 22.00
Beta	0.76
Analysts	Strong Buy
Price Target	24.00 (+49.44%)
Earnings Date	Aug 28, 2025

About MESO

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 81
• Stock Exchange: NASDAQ
• Ticker Symbol: MESO
• Website: https://www.mesoblast.com

Financial Performance

In 2025, Mesoblast's revenue was $17.20 million, an increase of 191.39% compared to the previous year's $5.90 million. Losses were -$102.14 million, 16.1% more than in 2024.

Analyst Summary

According to 2 analysts, the average rating for MESO stock is "Strong Buy." The 12-month stock price target is $24.0, which is an increase of 49.44% from the latest price.

Price Target

$24.0

(49.44% upside)

Analyst Consensus: Strong Buy